Pluristem Therapeutics analyst ratings
Pluristem Therapeutics analyst ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/20/2022 | 280.95% | Alliance Global Partners | $9.5 → $4 | Maintains | Buy |
| 05/04/2021 | 1090.48% | Alliance Global Partners | → $12.5 | Initiates Coverage On | → Buy |
| 12/10/2020 | 471.43% | Jefferies | → $6 | Downgrades | Buy → Hold |
| 12/10/2020 | 757.14% | HC Wainwright & Co. | $15.5 → $9 | Maintains | Buy |
| 07/24/2020 | 1423.81% | Jefferies | $12 → $16 | Maintains | Buy |
| 06/19/2020 | 1042.86% | Jefferies | → $12 | Initiates Coverage On | → Buy |
| 12/16/2019 | 1042.86% | Dawson James | → $12 | Initiates Coverage On | → Buy |
| 07/31/2018 | 328.57% | B. Riley Securities | → $4.5 | Initiates Coverage On | → Buy |
| 10/06/2017 | 376.19% | Seaport Global | → $5 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析師事務所 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 07/20/2022 | 280.95% | 聯盟全球合作伙伴 | 9.5 美元 → 4 美元 | 維護 | 購買 |
| 2021 年 4 月 5 日 | 1090.48% | 聯盟全球合作伙伴 | → 12.5 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2020 年 10 月 12 日 | 471.43% | 傑富瑞集團 | → 6 美元 | 降級 | 買入 → 持有 |
| 2020 年 10 月 12 日 | 757.14% | HC Wainwright & Co. | 15.5 美元 → 9 美元 | 維護 | 購買 |
| 07/24/2020 | 1423.81% | 傑富瑞集團 | 12 美元 → 16 美元 | 維護 | 購買 |
| 2020 年 6 月 19 日 | 1042.86% | 傑富瑞集團 | → 12 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2019 年 12 月 16 日 | 1042.86% | 道森·詹姆斯 | → 12 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 07/31/2018 | 328.57% | B. 萊利證券 | → 4.5 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 10/06/2017 | 376.19% | 海港全球 | → 5 美元 | 啓動覆蓋範圍開啓 | → 購買 |
Pluristem Therapeutics Questions & Answers
Pluristem Therapeutics 問答
The latest price target for Pluristem Therapeutics (NASDAQ: PSTI) was reported by Alliance Global Partners on July 20, 2022. The analyst firm set a price target for $4.00 expecting PSTI to rise to within 12 months (a possible 280.95% upside). 1 analyst firms have reported ratings in the last year.
Alliance Global Partners於2022年7月20日公佈了Pluristem Therapeutics（納斯達克股票代碼：PSTI）的最新目標股價。該分析公司將目標股價設定爲4.00美元，預計PSTI將在12個月內上漲至4美元（可能上漲280.95％）。去年有1家分析公司公佈了評級。
The latest analyst rating for Pluristem Therapeutics (NASDAQ: PSTI) was provided by Alliance Global Partners, and Pluristem Therapeutics maintained their buy rating.
Pluristem Therapeutics（納斯達克股票代碼：PSTI）的最新分析師評級由Alliance Global Partners提供，Pluristem Therapeutics維持買入評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pluristem Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pluristem Therapeutics was filed on July 20, 2022 so you should expect the next rating to be made available sometime around July 20, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Pluristem Therapeutics的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。Pluristem Therapeutics的最後一次評級是在2022年7月20日公佈的，因此您應該預計下一個評級將在2023年7月20日左右公佈。
While ratings are subjective and will change, the latest Pluristem Therapeutics (PSTI) rating was a maintained with a price target of $9.50 to $4.00. The current price Pluristem Therapeutics (PSTI) is trading at is $1.05, which is out of the analyst's predicted range.
儘管評級是主觀的，並將發生變化，但最新的Pluristem Therapeutics（PSTI）評級維持不變，目標股價爲9.50美元至4.00美元。Pluristem Therapeutics（PSTI）目前的交易價格爲1.05美元，超出了分析師的預期區間。